In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis

Motile bacteria can overcome diffusion resistances that substantially reduce the efficacy of standard cancer therapies. Many reports have also recently described the ability of Salmonella to deliver therapeutic molecules to tumors. Despite this potential, little is known about the spatiotemporal dynamics of bacterial accumulation in solid tumors. Ultimately this timing will affect how these microbes are used therapeutically. To determine how bacteria localize, we intravenously injected Salmonella typhimurium into BALB/c mice with 4T1 mammary carcinoma and measured the average bacterial content as a function of time. Immunohistochemistry was used to measure the extent of apoptosis, the average distance of bacteria from tumor vasculature and the location of bacteria in four different regions: the core, transition, body and edge. Bacteria accumulation was also measured in pulmonary and hepatic metastases. The doubling time of bacterial colonies in tumors was measured to be 16.8 h, and colonization was determined to delay tumor growth by 48 h. From 12 and 48 h after injection, the average distance between bacterial colonies and functional vasculature significantly increased from 130 to 310 μm. After 48 h, bacteria migrated away from the tumor edge toward the central core and induced apoptosis. After 96 h, bacteria began to marginate to the tumor transition zone. All observed metastases contained Salmonella and the extent of bacterial colocalization with metastatic tissue was 44% compared with 0.5% with normal liver parenchyma. These results demonstrate that Salmonella can penetrate tumor tissue and can selectively target metastases, two critical characteristics of a targeted cancer therapeutic.

[1]  Nicholas Denko,et al.  Overcoming Physiologic Barriers to Cancer Treatment by Molecularly Targeting the Tumor Microenvironment , 2006, Molecular Cancer Research.

[2]  M. Sporn,et al.  The tumour microenvironment as a target for chemoprevention , 2007, Nature Reviews Cancer.

[3]  Rachel W. Kasinskas,et al.  Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro , 2006, Biotechnology and bioengineering.

[4]  X. Luo,et al.  Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector. , 2001, Oncology research.

[5]  John Mao,et al.  Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Meng Yang,et al.  Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. , 2006, Cancer research.

[7]  Rachel W. Kasinskas,et al.  Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. , 2007, Cancer research.

[8]  N. Forbes Profile of a bacterial tumor killer , 2006, Nature Biotechnology.

[9]  D. Hicklin,et al.  Effect of p53 Status on Tumor Response to Antiangiogenic Therapy , 2002, Science.

[10]  S. Rosenberg,et al.  Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma. , 2003, Journal of immunotherapy.

[11]  N. Forbes,et al.  Single‐cell analysis demonstrates how nutrient deprivation creates apoptotic and quiescent cell populations in tumor cylindroids , 2008, Biotechnology and bioengineering.

[12]  M. Sznol,et al.  Use of preferentially replicating bacteria for the treatment of cancer. , 2000, The Journal of clinical investigation.

[13]  Qian Zhang,et al.  Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins , 2004, Nature Biotechnology.

[14]  Hyung-Seok Kim,et al.  Inhibition of tumor growth and metastasis by a combination of Escherichia coli-mediated cytolytic therapy and radiotherapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  C. Lewis,et al.  Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors , 2009, Gene Therapy.

[16]  T M Cole,et al.  A simple method for visualization of influential landmarks when using euclidean distance matrix analysis. , 1998, American journal of physical anthropology.

[17]  R. Jain,et al.  Can engineered bacteria help control cancer? , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  X. Luo,et al.  Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. , 2000, The Journal of infectious diseases.

[19]  Mark W Dewhirst,et al.  Intravascular location of breast cancer cells after spontaneous metastasis to the lung. , 2002, The American journal of pathology.

[20]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[21]  Samuel I. Miller,et al.  Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo , 1999, Nature Biotechnology.

[22]  Meng Yang,et al.  Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Pawelek,et al.  Tumor-targeted Salmonella as a novel anticancer vector. , 1997, Cancer research.

[24]  S. Rosenberg,et al.  Antitumor Effects in Mice of the Intravenous Injection of Attenuated Salmonella Typhimurium , 2002, Journal of immunotherapy.

[25]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[26]  R. Rubin The war on cancer. , 1996, U.S. news & world report.

[27]  Paul J. Williams,et al.  Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma , 2000, Cancer.

[28]  P. Vaupel,et al.  Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. , 2004, The oncologist.

[29]  A. Shiau,et al.  Salmonella choleraesuis as an anticancer agent in a syngeneic model of orthotopic hepatocellular carcinoma , 2008, International journal of cancer.

[30]  L. Chung,et al.  Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. , 2007, Current problems in cancer.

[31]  John Calvin Reed,et al.  Inhibition of Tumor Growth Using Salmonella Expressing Fas Ligand , 2008, Journal of the National Cancer Institute.

[32]  Dai Fukumura,et al.  Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors. , 2003, Cancer research.

[33]  N. Forbes,et al.  Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice , 2009, British Journal of Cancer.

[34]  Jochen Stritzker,et al.  Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. , 2007, International journal of medical microbiology : IJMM.